Press releases
- Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
- Outcome of Innate Pharma’s 2024 Annual General Meeting
- Innate Pharma: Clarification Regarding SAR443579 Designation
- Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
- Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
- Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
- Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
- Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
- Innate Pharma Announces Its Participation in Upcoming Investor Conference
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 80.86m |
Free float | 60.59m |
P/E (TTM) | -- |
Market cap | 215.90m EUR |
EPS (TTM) | -0.0939 EUR |
Data delayed at least 15 minutes.
More ▼